Related News
UK health body rejects Herceptin for gastric cancer
Source: Agencies |
July 6, 2010, Tuesday
|
Online Edition
Online Edition
BRITAIN'S health cost watchdog has rejected Roche's cancer drug Herceptin for patients with stomach cancer, which means they will not get the drug paid for by the country's taxpayer-funded National Health Service (NHS).
The National Institute for Health and Clinical Excellence (NICE) said today it was rejecting the drug, whose generic name is trastuzumab, for gastric cancer "due to the uncertainty surrounding the extent to which it can extend life".
Herceptin only works in cancer patients whose tumours have high levels of a protein called human epidermal growth factor receptor 2, or HER2, and is not suitable for others.
It was approved for NHS funding for the early treatment of women with HER2-positive breast cancer in June 2006 after a long battle by cancer campaigners for NICE to recommend it.
"Although clinical trials suggest that trastuzumab can extend life for patients with HER2-positive metastatic gastric cancer, there is considerable uncertainty about the data on how long this extension would be," NICE Chief Executive Andrew Dillon said in a statement.
He said the drug's manufacturer, Roche, and other parties would now have an opportunity to resolve this uncertainty by providing more information to NICE's appraisal committee.
According to NICE, gastric cancer affects around 8,200 people in the United Kingdom every year, around 500 of whom would be eligible for treatment with Herceptin.
The drug, which is given by injection, works by attaching itself to the HER2 protein to stop the cancer cells from growing.
A 150-mg vial of Herceptin costs around 407.40 pounds (US$630), and according to NICE, the total cost of Herceptin per patient is around 10,185 pounds.
The National Institute for Health and Clinical Excellence (NICE) said today it was rejecting the drug, whose generic name is trastuzumab, for gastric cancer "due to the uncertainty surrounding the extent to which it can extend life".
Herceptin only works in cancer patients whose tumours have high levels of a protein called human epidermal growth factor receptor 2, or HER2, and is not suitable for others.
It was approved for NHS funding for the early treatment of women with HER2-positive breast cancer in June 2006 after a long battle by cancer campaigners for NICE to recommend it.
"Although clinical trials suggest that trastuzumab can extend life for patients with HER2-positive metastatic gastric cancer, there is considerable uncertainty about the data on how long this extension would be," NICE Chief Executive Andrew Dillon said in a statement.
He said the drug's manufacturer, Roche, and other parties would now have an opportunity to resolve this uncertainty by providing more information to NICE's appraisal committee.
According to NICE, gastric cancer affects around 8,200 people in the United Kingdom every year, around 500 of whom would be eligible for treatment with Herceptin.
The drug, which is given by injection, works by attaching itself to the HER2 protein to stop the cancer cells from growing.
A 150-mg vial of Herceptin costs around 407.40 pounds (US$630), and according to NICE, the total cost of Herceptin per patient is around 10,185 pounds.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
